Deutetrabenazine

🧮 Dose calculator

Huntington disease chorea · Regimen source: FDA Austedo · 2.1

• • With food; 12 mg/day or more in two doses. XR once daily. Strong CYP2D6 inhibitors or poor metabolizers: max 36 mg. Switching from tetrabenazine per label Table 2. FDA Austedo · 2.1FDA Austedo · 2.2FDA Austedo · 2.3

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Austedo · 8.1

  “Risk Summary There are no adequate data on the developmental risk associated with the use of AUSTEDO XR or AUSTEDO in pregnant women.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Austedo · 8.2

  “Risk Summary There are no data on the presence of deutetrabenazine or its metabolites in human milk, the effects on the breastfed infant, or the effects of the drug on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Austedo · 8.4

  “Chorea associated with Huntington’s Disease and Tardive Dyskinesia The safety and effectiveness of AUSTEDO XR and AUSTEDO have not been established in pediatric patients for the treatment of chorea associated with Huntington’s disease or for the treatment of tardive dyskinesia.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Austedo · 8.5

  “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of hepatic, renal, and cardiac dysfunction, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.